ReviewActa paediatrica (Oslo, Norway : 1992)2026
Exploring the Development of Vaccine Platforms, With a Particular Focus on the COVID-19 Pandemic.
Review in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Vaccines have been a cornerstone of human health for more than 200 years and one of the most important tools to reduce childhood deaths caused by pathogens. The concept of vaccines is basically to take something safe, make it immunogenic and induce an immune response in the host that will protect it against something dangerous. Live attenuated vaccines were the only option two centuries ago. These are excellent, and possibly the best vaccine platform, but they have limitations as they cannot always be given to everyone safely, for example due to deficient immunity or pregnancy. That is why newer platforms, such as killed or inactivated vaccines, were developed. These provide better all-round safety, but are often less immunogenic and require additional doses. Subcomponent vaccines were then developed in the 1980s. These only used parts of the virus, further improving safety and introducing the possibility of producing vaccines using gene technology. Adding genetic vaccines to the toolbox revolutionized the way that we handled the COVID-19 pandemic. The host became the producer of the vaccine, which better mimicked the immune responses induced by the live attenuated vaccines. All these platforms will be discussed in this mini-review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.